Kala Bio (KALA) Income from Continuing Operations (2016 - 2026)
Kala Bio (KALA) posted Income from Continuing Operations of 1728000.0 for Q1 2026, up 84.0% sequentially from 10800000.0 in Q4 2025, and up 84.7% YoY from 935551.42 in Q1 2025.
Kala Bio (KALA) Income from Continuing Operations (2016 - 2026) Analysis & Trends
Kala Bio has reported Income from Continuing Operations for 11 years, with the latest figure at 1728000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 84.7% year-over-year to 1728000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 32162000.0 (up 25.42% YoY) and the FY2025 annual result came in at 184884000.0, down 3.61% from the prior year.
- Income from Continuing Operations grew to 1728000.0 in Q1 2026 per KALA's latest filing, from 10800000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 1728000.0 in Q1 2026 and troughed at 32941000.0 in Q1 2022.
- A 5-year average of 12819705.88 and a median of 10800000.0 in 2025 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2026: Income from Continuing Operations declined 14.54% in 2024, then soared 84.7% in 2026.
- Over 5 years, Income from Continuing Operations stood at 10166000.0 in 2022, then slipped by 3.06% to 10477000.0 in 2023, then climbed by 0.99% to 10373000.0 in 2024, then declined by 4.12% to 10800000.0 in 2025, then soared by 84.0% to 1728000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 1728000.0, 10800000.0, and 7932000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Kala Bio | 9.89 Mn | 9.89 Mn | - | -1.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.73 Mn |
| Dec 31, 2025 | -10.80 Mn |
| Sep 30, 2025 | -7.93 Mn |
| Jun 30, 2025 | -11.70 Mn |
| Mar 31, 2025 | -11.30 Mn |
| Dec 31, 2024 | -10.37 Mn |
| Sep 30, 2024 | -10.90 Mn |
| Jun 30, 2024 | -10.56 Mn |
| Mar 31, 2024 | -12.88 Mn |
| Dec 31, 2023 | -10.48 Mn |
| Sep 30, 2023 | -9.51 Mn |
| Jun 30, 2023 | -10.29 Mn |
| Mar 31, 2023 | -12.48 Mn |
| Dec 31, 2022 | -10.17 Mn |
| Sep 30, 2022 | -15.78 Mn |
| Jun 30, 2022 | -28.11 Mn |
| Mar 31, 2022 | -32.94 Mn |
| Dec 31, 2021 | -48.95 Mn |
| Sep 30, 2021 | -28.27 Mn |
| Jun 30, 2021 | -31.23 Mn |